Clinical Trials Logo

Hodgkin's Lymphoma clinical trials

View clinical trials related to Hodgkin's Lymphoma.

Filter by:

NCT ID: NCT01788839 Recruiting - Breast Cancer Clinical Trials

Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma

Start date: February 2013
Phase:
Study type: Observational

The purpose of this study is to see how cancer treatment affects sexual and reproductive function. The patient will also be asked to participate in blood draws to see if and how cancer treatment affects the ovaries and the ability to have children (fertility). These blood draws are optional and the patient can still participate in the questionnaire portion of the study even if they choose not to have their blood drawn.

NCT ID: NCT01399931 Recruiting - Hodgkin's Lymphoma Clinical Trials

Dual Point PET Scan in Early Stage Hodgkin Lymphoma Patients With Bulky Lesions

2P-HD-10
Start date: January 2012
Phase: N/A
Study type: Observational

To assess specificity and overall accuracy of interim dual-point acquisition PET in predicting treatment outcome. The study is aimed at assessing the specificity of interim dual-point PET performed after 2 ABVD cycles to predict treatment outcome in early-stage Hodgkin's Lymphoma patients presenting bulky lesions at baseline.

NCT ID: NCT01300156 Recruiting - Hodgkin's Lymphoma Clinical Trials

Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin (ESHAOx) for Refractory or Relapsed Hodgkin's Lymphoma (HL)

Start date: February 2011
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of combination chemotherapy with etoposide, methylprednisolone, high-dose cytarabine and oxaliplatin (ESHAOx) for patients with refractory or relapsed Hodgkin's lymphoma (HL).

NCT ID: NCT00981760 Recruiting - Multiple Myeloma Clinical Trials

Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following Nonmyeloablative Allogeneic Stem Cell Transplantation

Start date: July 2008
Phase: Phase 2/Phase 3
Study type: Interventional

One risk of a stem cell transplant is that the donated stem cells do not grow in the recipient. This is called graft rejection. Previous laboratory research has suggested that the reaction between the recipient's cells and the donor's cells that causes graft rejection is associated with an anti-cancer effect. In this research study the investigators will give participants some of their own white blood cells after their transplant. This is called a recipient leukocyte infusion (RLI). This is done to cause the participant's immune system to react against the donor's cells and reject the transplant. The purpose of this research study is to learn if the graft rejection has an anti-cancer effect.

NCT ID: NCT00441818 Recruiting - Hodgkin's Lymphoma Clinical Trials

Safety and Efficacy Study of TNX-650 to Treat Refractory Hodgkin's Lymphoma

Start date: May 2006
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine the safety and effectiveness of TNX-650 for Injection when administered to patients with refractory Hodgkin's lymphoma.